<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697810</url>
  </required_header>
  <id_info>
    <org_study_id>CF102-212LD</org_study_id>
    <nct_id>NCT04697810</nct_id>
  </id_info>
  <brief_title>Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with biopsy-proven NASH will be randomly assigned in a 2:1 ratio to oral doses of&#xD;
      namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36 weeks. Subjects&#xD;
      will be evaluated regularly for safety, and efficacy biomarkers will be measured at Baseline&#xD;
      and Weeks 6, 12, 24, and 36. At Week 36, all subjects will undergo liver biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with a&#xD;
      diagnosis of NASH and F1-3 fibrosis. Subjects will undergo Screening procedures during the 6&#xD;
      weeks preceding Baseline. Subjects (n = ~114) will be randomly assigned in a 2:1 ratio to&#xD;
      oral doses of namodenoson 25 mg every 12 hours or matching placebo every 12 hours for 36&#xD;
      weeks. Subjects will be evaluated regularly for safety, and efficacy biomarkers will be&#xD;
      measured at Baseline and Weeks 6, 12, 24, and 36. At Week 36, all subjects will undergo&#xD;
      post-treatment liver biopsy, which will be interpreted by a blinded expert hepatopathologist.&#xD;
      Subjects will return for a follow-up visit 6 weeks after completion of the last dose of study&#xD;
      drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomly assigned in a 2:1 ratio of namodenoson 25 mg or matching placebo, according to a computer-generated randomization schedule. Blocked randomization will be programmed using a pre-specified block size. Double-blinding will be maintained throughout the trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo capsules are identical in appearance to namodenoson capsules.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Non-Alcoholic Fatty Liver Disease (NAFLD) activity score (NAS)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Proportion of subjects who achieve a ≥2-point improvement in the non-alcoholic fatty liver disease (NAFLD) activity score (NAS) of the Non-Alcoholic Steatohepatitis Clinical Research Network (NASH CRN)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Incidence of AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine transaminase (ALT) mean</measure>
    <time_frame>36 weeks</time_frame>
    <description>Mean percent change from Baseline in serum ALT level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state blood level of namodenoson</measure>
    <time_frame>36 weeks</time_frame>
    <description>Plasma trough concentration (ng/mL) of namodenoson taken at pre-dose samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ALT absolute</measure>
    <time_frame>36 weeks</time_frame>
    <description>Absolute change from Baseline in serum ALT</description>
  </other_outcome>
  <other_outcome>
    <measure>ALT threshold</measure>
    <time_frame>36 weeks</time_frame>
    <description>Proportion of subjects who achieve ≥17-point reduction from Baseline in serum ALT</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in body weight</description>
  </other_outcome>
  <other_outcome>
    <measure>Adiponectin</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in serum adiponectin level</description>
  </other_outcome>
  <other_outcome>
    <measure>Released N-terminal pro-peptide of type III collagen neoepitope (Pro-C3)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in Pro-C3</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Enhanced Liver Fibrosis (ELF) Score</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in ELF Score, which is a continuous scale starting at zero, with higher scores indicating more severe disease</description>
  </other_outcome>
  <other_outcome>
    <measure>FibroScan controlled attenuation parameter (CAP)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in CAP</description>
  </other_outcome>
  <other_outcome>
    <measure>FibroScan-AST (FAST) Score</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in FAST Score, which is a decimal score from 0 to 1, with higher scores indicating more severe disease</description>
  </other_outcome>
  <other_outcome>
    <measure>Aspartate transaminase (AST)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in serum AST</description>
  </other_outcome>
  <other_outcome>
    <measure>Gamma-glutamyl transferase (GGT)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in serum GGT</description>
  </other_outcome>
  <other_outcome>
    <measure>Fibrosis-4 (Fib-4) Index</measure>
    <time_frame>36 weeks</time_frame>
    <description>Change from Baseline in Fib-4 Index</description>
  </other_outcome>
  <other_outcome>
    <measure>NASH resolution</measure>
    <time_frame>36 weeks</time_frame>
    <description>Proportion of subjects who achieve histologic NASH resolution as defined by a ballooning score of 0 and an inflammation score of 0-1 without worsening of fibrosis</description>
  </other_outcome>
  <other_outcome>
    <measure>NASH fibrosis improvement</measure>
    <time_frame>36 weeks</time_frame>
    <description>Proportion of subjects who achieve histologic NASH improvement by at least 1 point without worsening of NASH</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Namodenoson</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Namodenoson capsules orally 25 mg every 12 hours for 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo capsules orally 25 mg every 12 hours for 36 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Namodenoson</intervention_name>
    <description>25 mg q12hours x 36 weeks</description>
    <arm_group_label>Namodenoson</arm_group_label>
    <other_name>CF102</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching capsules q12hours x 36 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 18 years of age.&#xD;
&#xD;
          2. AST at Screening of ≥20 IU/L.&#xD;
&#xD;
          3. FibroScan LSM ≥8.5 kPa&#xD;
&#xD;
          4. Diagnosis of NASH by biopsy at Screening showing NAS ≥4 by central read, with a score&#xD;
             of at least 1 point in each of the 3 histologic categories of steatosis, inflammation,&#xD;
             and hepatocellular ballooning (Kleiner 2005). If the subject has had a qualifying&#xD;
             liver biopsy within 6 months prior to Baseline and the slides are available for&#xD;
             central read prior to randomization, this biopsy can be waived.&#xD;
&#xD;
          5. Concomitant biopsy-proven Stage 1-3 hepatic fibrosis by NASH CRN criteria by central&#xD;
             read (Kleiner 2005).&#xD;
&#xD;
          6. At least 2 of the following criteria for the metabolic syndrome:&#xD;
&#xD;
               -  Obesity, defined waist circumference &gt;88 cm for women or &gt;102 cm for men&#xD;
&#xD;
               -  Hypertriglyceridemia, defined as &gt;150 mg/dL (&gt;1.7 mmol/L) or on drug treatment&#xD;
                  for hypertriglyceridemia&#xD;
&#xD;
               -  Reduced high-density lipoprotein (HDL) cholesterol, defined as &lt;40 mg/dL (&lt;1.03&#xD;
                  mmol/L) in men or &lt;50 mg/dL (&lt;1.3 mmol/L) in women&#xD;
&#xD;
               -  History of hypertension, currently controlled in the judgment of the Investigator&#xD;
&#xD;
               -  Elevated fasting glucose, defined as ≥100 mg/dL (≥5.6 mmol/L).&#xD;
&#xD;
          7. Acceptable hepatic metabolic and synthetic function, as indicated at Screening by:&#xD;
&#xD;
               -  Serum albumin ≥3.5 gm/dL&#xD;
&#xD;
               -  International normalized ratio ≤1.3&#xD;
&#xD;
               -  Serum total bilirubin ≤2.0 mg/dL (unless subject has known Gilbert's Syndrome).&#xD;
&#xD;
          8. The following laboratory values must be documented at Screening:&#xD;
&#xD;
               -  Absolute neutrophil count at least 1.0 x 109/L&#xD;
&#xD;
               -  Platelet count at least 150 x 109/L&#xD;
&#xD;
               -  Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2&#xD;
&#xD;
          9. Female subjects may be enrolled if they are not of childbearing potential, permanently&#xD;
             sterile or are post-menopausal, defined as no menses for at least 1 year without an&#xD;
             alternative medical cause and FSH levels in the post-menopausal range.&#xD;
&#xD;
         10. Male subjects must refrain from sperm donation during treatment and until at least 90&#xD;
             days after the end of study drug dosing. Male subjects with fertile or pregnant&#xD;
             partners must agree to use condoms throughout the course of the trial and for 3 months&#xD;
             after.&#xD;
&#xD;
         11. Patients taking herbal supplements, homeopathic medications, or other alternative&#xD;
             treatments, must be on a stable regimen for at least 3 months prior to randomization.&#xD;
&#xD;
         12. Understand and provide written informed consent to participate.&#xD;
&#xD;
         13. Willing to undergo 2 liver biopsies.&#xD;
&#xD;
         14. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and&#xD;
             other study-related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ascites, hepatic encephalopathy, or other clinical evidence of cirrhosis.&#xD;
&#xD;
          2. Other active acute or chronic liver disease, such as autoimmune hepatitis, hepatitis&#xD;
             B, hepatitis C, alcoholic liver disease, or hepatocellular carcinoma.&#xD;
&#xD;
          3. Seropositivity for markers of viral hepatitis or human immunodeficiency virus (HIV) at&#xD;
             Screening.&#xD;
&#xD;
          4. Weight loss of &gt;5% within 3 months prior to Baseline.&#xD;
&#xD;
          5. History of bariatric surgery within 5 years of Screening.&#xD;
&#xD;
          6. Diabetes mellitus other than Type II.&#xD;
&#xD;
          7. Hemoglobin A1c &gt;9.0% (subjects with diabetes).&#xD;
&#xD;
          8. Any contraindication to percutaneous liver biopsy.&#xD;
&#xD;
          9. Daily alcohol intake &gt;20 g (2 units)/day for women and 30 g (3 units)/day for men (on&#xD;
             average), as per Alcohol Use Disorders Identification Test (AUDIT) questionnaire.&#xD;
&#xD;
         10. Treatment with therapeutic doses of Vitamin E (≥800-1000 IU daily), or any of the&#xD;
             following anti-diabetic medications: GLP-1 receptor agonists (such as Januvia&#xD;
             [sitagliptin], Byetta [incretin], etc.), pioglitazone, or SGLT2 inhibitors&#xD;
             (&quot;gliflozin&quot; drugs); unless the dose and regimen has been stable for at least 3&#xD;
             months.&#xD;
&#xD;
         11. Active rheumatoid arthritis treated with small-molecule (including methotrexate) or&#xD;
             biologic disease-modifying anti-rheumatic agent concurrently or within 1 year.&#xD;
&#xD;
         12. Use of any immunosuppressive medication, anti-inflammatory monoclonal antibody&#xD;
             treatment, or chronic systemic corticosteroids &gt;10 mg prednisone-equivalent&#xD;
             concurrently or within 1 year.&#xD;
&#xD;
         13. More than 7 days of treatment with valproic acid, tamoxifen, amiodarone, or&#xD;
             anti-cholinergic agents within 3 months.&#xD;
&#xD;
         14. Uncontrolled or clinically unstable thyroid disease.&#xD;
&#xD;
         15. Uncontrolled arterial hypertension or congestive heart failure (New York Heart&#xD;
             Association Classification 3 or 4), or other heart disease which is, in the&#xD;
             Investigator's judgment, clinically unstable.&#xD;
&#xD;
         16. Angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery&#xD;
             bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3&#xD;
             months.&#xD;
&#xD;
         17. QTcF interval on Screening Visit ECG or an average of triplicate Baseline Visit ECGs &gt;&#xD;
             450 milliseconds (msec) for males or &gt; 470 msec for females.&#xD;
&#xD;
         18. A condition which increases proarrhythmic risk, including hypokalemia, hypomagnesemia,&#xD;
             or congenital Long QT Syndrome.&#xD;
&#xD;
         19. Ongoing or planned use of a concomitant medication that is on the CredibleMedsTM list&#xD;
             of drugs known to cause Torsades des Pointes.&#xD;
&#xD;
         20. Active gastrointestinal disease which could interfere with the absorption of oral&#xD;
             medication.&#xD;
&#xD;
         21. Any severe, acute, or chronic medical or psychiatric condition, or laboratory&#xD;
             abnormality that would make the patient inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioStrategics Consulting Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zivit Harpaz</last_name>
    <phone>+972-3-9241114</phone>
    <email>Zivit@canfite.co.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pnina Fishman, PhD</last_name>
    <phone>+972-3-9241114</phone>
    <email>pnina@canfite.co.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Rifaat Safadi, MD</last_name>
      <phone>+972-2-6777721</phone>
      <email>safadi@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Rami Ghantous</last_name>
      <phone>+972-54-7748258</phone>
      <email>ramighantous@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://canfite.co.il</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 2011 Sep;226(9):2438-47. doi: 10.1002/jcp.22593.</citation>
    <PMID>21660967</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

